These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 33012172

  • 1. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation.
    Yao X, Inselman JW, Ross JS, Izem R, Graham DJ, Martin DB, Thompson AM, Ross Southworth M, Siontis KC, Ngufor CG, Nath KA, Desai NR, Nallamothu BK, Saran R, Shah ND, Noseworthy PA.
    Circ Cardiovasc Qual Outcomes; 2020 Oct; 13(10):e006515. PubMed ID: 33012172
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.
    J Am Heart Assoc; 2016 Jun 13; 5(6):. PubMed ID: 27412905
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 13; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH, Skjøth F, Nielsen PB, Kjældgaard JN, Larsen TB.
    JAMA Cardiol; 2017 Aug 01; 2(8):872-881. PubMed ID: 28614582
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF, Chan YH, Chang SH, Tu HT, Chen SW, Yeh YH, Wu LS, Kuo CF, Kuo CT, See LC.
    J Am Heart Assoc; 2019 Mar 05; 8(5):e011112. PubMed ID: 30834802
    [Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S, Katada J, Saito K, Jenkins A, Li B, Mardekian J, Terayama Y.
    Open Heart; 2020 Mar 05; 7(1):e001232. PubMed ID: 32341789
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z, Papuga-Szela E, Krzysztof P, Anetta U.
    J Cardiovasc Pharmacol; 2020 Dec 05; 76(6):671-677. PubMed ID: 33284572
    [Abstract] [Full Text] [Related]

  • 8. The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
    Harel Z, McArthur E, Jeyakumar N, Sood MM, Garg AX, Silver SA, Dorian P, Blum D, Beaubien-Souligny W, Yan AT, Badve SV, Smyth B, Jun M, Jandoc R, Kitchlu A, Wald R.
    Clin J Am Soc Nephrol; 2021 Oct 05; 16(10):1470-1479. PubMed ID: 34407990
    [Abstract] [Full Text] [Related]

  • 9. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
    Cheung CL, Sing CW, Lau WCY, Li GHY, Lip GYH, Tan KCB, Cheung BMY, Chan EWY, Wong ICK.
    Cardiovasc Diabetol; 2021 Mar 25; 20(1):71. PubMed ID: 33766030
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Nadkarni A, Shank TC.
    BMC Cardiovasc Disord; 2019 Jun 13; 19(1):142. PubMed ID: 31195999
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH, See LC, Tu HT, Yeh YH, Chang SH, Wu LS, Lee HF, Wang CL, Kuo CF, Kuo CT.
    J Am Heart Assoc; 2018 Apr 05; 7(8):. PubMed ID: 29622587
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK, Sood NA, Bunz TJ, Coleman CI.
    J Am Heart Assoc; 2018 Apr 13; 7(8):. PubMed ID: 29654196
    [Abstract] [Full Text] [Related]

  • 13. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC, Ahmad A, Petrini M, Tang W, Evans A, Rush T, Thompson D, Oh K, Schwartzman E.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):80-90. PubMed ID: 30500885
    [Abstract] [Full Text] [Related]

  • 14. Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.
    Xu Y, Ballew SH, Chang AR, Inker LA, Grams ME, Shin JI.
    J Am Heart Assoc; 2024 Aug 20; 13(16):e034641. PubMed ID: 39119973
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
    Rutherford OW, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S.
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr 01; 6(2):75-85. PubMed ID: 31942972
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
    Huang HK, Liu PP, Hsu JY, Lin SM, Peng CC, Wang JH, Yeh JI, Loh CH.
    J Am Heart Assoc; 2020 Jan 21; 9(2):e013845. PubMed ID: 31918601
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.